1107 related articles for article (PubMed ID: 18573246)
1. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.
Antal-Zimanyi I; Bruce MA; Leboulluec KL; Iben LG; Mattson GK; McGovern RT; Hogan JB; Leahy CL; Flowers SC; Stanley JA; Ortiz AA; Poindexter GS
Eur J Pharmacol; 2008 Aug; 590(1-3):224-32. PubMed ID: 18573246
[TBL] [Abstract][Full Text] [Related]
2. L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist.
Kanatani A; Ishihara A; Iwaasa H; Nakamura K; Okamoto O; Hidaka M; Ito J; Fukuroda T; MacNeil DJ; Van der Ploeg LH; Ishii Y; Okabe T; Fukami T; Ihara M
Biochem Biophys Res Commun; 2000 May; 272(1):169-73. PubMed ID: 10872822
[TBL] [Abstract][Full Text] [Related]
3. The novel neuropeptide Y Y(1) receptor antagonist J-104870: a potent feeding suppressant with oral bioavailability.
Kanatani A; Kanno T; Ishihara A; Hata M; Sakuraba A; Tanaka T; Tsuchiya Y; Mase T; Fukuroda T; Fukami T; Ihara M
Biochem Biophys Res Commun; 1999 Dec; 266(1):88-91. PubMed ID: 10581170
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization and feeding-suppressive property of FMS586 [3-(5,6,7,8-tetrahydro-9-isopropyl-carbazol-3-yl)-1-methyl-1-(2-pyridin-4-yl-ethyl)-urea hydrochloride], a novel, selective, and orally active antagonist for neuropeptide Y Y5 receptor.
Kakui N; Tanaka J; Tabata Y; Asai K; Masuda N; Miyara T; Nakatani Y; Ohsawa F; Nishikawa N; Sugai M; Suzuki M; Aoki K; Kitaguchi H
J Pharmacol Exp Ther; 2006 May; 317(2):562-70. PubMed ID: 16436501
[TBL] [Abstract][Full Text] [Related]
5. Evidence for involvement of neuropeptide Y receptors in the regulation of food intake: studies with Y1-selective antagonist BIBP3226.
Kask A; Rägo L; Harro J
Br J Pharmacol; 1998 Aug; 124(7):1507-15. PubMed ID: 9723965
[TBL] [Abstract][Full Text] [Related]
6. Involvement of neuropeptide Y Y(1) receptors in the acute, chronic and withdrawal effects of nicotine on feeding and body weight in rats.
Nakhate KT; Dandekar MP; Kokare DM; Subhedar NK
Eur J Pharmacol; 2009 May; 609(1-3):78-87. PubMed ID: 19285064
[TBL] [Abstract][Full Text] [Related]
7. Identification of potent and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo.
Mullins D; Kirby D; Hwa J; Guzzi M; Rivier J; Parker E
Mol Pharmacol; 2001 Sep; 60(3):534-40. PubMed ID: 11502885
[TBL] [Abstract][Full Text] [Related]
8. Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor.
Criscione L; Rigollier P; Batzl-Hartmann C; Rüeger H; Stricker-Krongrad A; Wyss P; Brunner L; Whitebread S; Yamaguchi Y; Gerald C; Heurich RO; Walker MW; Chiesi M; Schilling W; Hofbauer KG; Levens N
J Clin Invest; 1998 Dec; 102(12):2136-45. PubMed ID: 9854049
[TBL] [Abstract][Full Text] [Related]
9. A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents.
Ortiz AA; Milardo LF; DeCarr LB; Buckholz TM; Mays MR; Claus TH; Livingston JN; Mahle CD; Lumb KJ
J Pharmacol Exp Ther; 2007 Nov; 323(2):692-700. PubMed ID: 17671099
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis.
Mashiko S; Moriya R; Ishihara A; Gomori A; Matsushita H; Egashira S; Iwaasa H; Takahashi T; Haga Y; Fukami T; Kanatani A
Eur J Pharmacol; 2009 Aug; 615(1-3):113-7. PubMed ID: 19482021
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of pseudoirreversible nonpeptide antagonists of the neuropeptide Y Y5 receptor and development of a novel Y5-selective radioligand.
Mullins D; Adham N; Hesk D; Wu Y; Kelly J; Huang Y; Guzzi M; Zhang X; McCombie S; Stamford A; Parker E
Eur J Pharmacol; 2008 Dec; 601(1-3):1-7. PubMed ID: 18976648
[TBL] [Abstract][Full Text] [Related]
12. Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a small molecule antagonist of the neuropeptide Y Y2 receptor.
Bonaventure P; Nepomuceno D; Mazur C; Lord B; Rudolph DA; Jablonowski JA; Carruthers NI; Lovenberg TW
J Pharmacol Exp Ther; 2004 Mar; 308(3):1130-7. PubMed ID: 14617685
[TBL] [Abstract][Full Text] [Related]
13. Neuropeptide Y as a partial agonist of the Y1 receptor.
Sah R; Balasubramaniam A; Parker MS; Sallee F; Parker SL
Eur J Pharmacol; 2005 Nov; 525(1-3):60-8. PubMed ID: 16293244
[TBL] [Abstract][Full Text] [Related]
14. Effects of a selective melanin-concentrating hormone 1 receptor antagonist on food intake and energy homeostasis in diet-induced obese mice.
Kowalski TJ; Spar BD; Weig B; Farley C; Cook J; Ghibaudi L; Fried S; O'Neill K; Del Vecchio RA; McBriar M; Guzik H; Clader J; Hawes BE; Hwa J
Eur J Pharmacol; 2006 Mar; 535(1-3):182-91. PubMed ID: 16540104
[TBL] [Abstract][Full Text] [Related]
15. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake.
Abbott CR; Small CJ; Kennedy AR; Neary NM; Sajedi A; Ghatei MA; Bloom SR
Brain Res; 2005 May; 1043(1-2):139-44. PubMed ID: 15862527
[TBL] [Abstract][Full Text] [Related]
16. The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 [N-[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]methyl]-methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of stress sensitivity.
Walker MW; Wolinsky TD; Jubian V; Chandrasena G; Zhong H; Huang X; Miller S; Hegde LG; Marsteller DA; Marzabadi MR; Papp M; Overstreet DH; Gerald CP; Craig DA
J Pharmacol Exp Ther; 2009 Mar; 328(3):900-11. PubMed ID: 19098165
[TBL] [Abstract][Full Text] [Related]
17. Importance of orexigenic counter-regulation for multiple targeted feeding inhibition.
Schusdziarra V; Zimmermann JP; Schick RR
Obes Res; 2004 Apr; 12(4):627-32. PubMed ID: 15090630
[TBL] [Abstract][Full Text] [Related]
18. Enhanced effect of neuropeptide Y on food intake caused by blockade of the V(1A) vasopressin receptor.
Aoyagi T; Kusakawa S; Sanbe A; Hiroyama M; Fujiwara Y; Yamauchi J; Tanoue A
Eur J Pharmacol; 2009 Nov; 622(1-3):32-6. PubMed ID: 19766110
[TBL] [Abstract][Full Text] [Related]
19. Dihydropyridine neuropeptide Y Y(1) receptor antagonists.
Poindexter GS; Bruce MA; LeBoulluec KL; Monkovic I; Martin SW; Parker EM; Iben LG; McGovern RT; Ortiz AA; Stanley JA; Mattson GK; Kozlowski M; Arcuri M; Antal-Zimanyi I
Bioorg Med Chem Lett; 2002 Feb; 12(3):379-82. PubMed ID: 11814801
[TBL] [Abstract][Full Text] [Related]
20. WAY-163909 [(7bR, 10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole], a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity.
Dunlop J; Sabb AL; Mazandarani H; Zhang J; Kalgaonker S; Shukhina E; Sukoff S; Vogel RL; Stack G; Schechter L; Harrison BL; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2005 May; 313(2):862-9. PubMed ID: 15705738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
